Table 5.
—Analysis of Factors Associated With Complications During the Diagnostic Evaluation
| Univariate Analysis | Multivariate Analysis | |||
| Variable | OR (95% CI) | P Value | OR (95% CI) | P Value |
| Age, y | ||||
| 71-75 vs 66-70 | 1.14 (1.02-1.26) | .02 | … | … |
| 76-80 vs 66-70 | 1.11 (0.99-1.25) | .06 | … | … |
| >80 vs 66-70 | 1.16 (1.02-1.32) | .03 | … | … |
| Female vs male | 1.04 (0.96-1.13) | .35 | … | … |
| Year of diagnosis vs 1995-1996 | ||||
| 1997 | 2.31 (1.69-3.16) | < .0001 | 2.38 (1.73-3.28) | < .0001 |
| 1998 | 1.66 (1.19-2.32) | .0032 | 1.73 (1.23-2.42) | .002 |
| 1999 | 2.28 (1.63-3.17) | < .0001 | 2.43 (1.73-3.41) | < .0001 |
| 2000 | 2.06 (1.58-2.70) | < .0001 | 2.29 (1.73-3.01) | < .0001 |
| 2001 | 1.76 (1.37-2.26) | < .0001 | 2.17 (1.67-2.82) | < .0001 |
| 2002 | 2.01 (1.57-2.58) | < .0001 | 2.45 (1.89-3.18) | < .0001 |
| 2003 | 1.96 (1.53-2.51) | < .0001 | 2.41 (1.86-3.13) | < .0001 |
| 2004 | 2.05 (1.61-2.62) | < .0001 | 2.24 (1.73-2.89) | < .0001 |
| 2005 | 2.30 (1.81-2.94) | < .0001 | 2.41 (1.87-3.11) | < .0001 |
| 2006 | 2.01 (1.57-2.57) | < .0001 | 2.13 (1.64-2.76) | < .0001 |
| 2007 | 2.19 (1.72-2.81) | < .0001 | 2.31 (1.79-2.99) | < .0001 |
| Race vs non-Hispanic white | ||||
| Hispanic | 1.03 (0.85-1.25) | .76 | 0.97 (0.79-1.19) | .77 |
| Non-Hispanic black | 0.72 (0.60-0.86) | .0002 | 0.68 (0.56-0.81) | < .0001 |
| Non-Hispanic other | 1.09 (0.88-1.36) | .42 | 0.96 (0.75-1.22) | .71 |
| Geographic region vs California | ||||
| Atlanta and rural Georgia | 0.71 (0.55-0.92) | .01 | 0.73 (0.56-0.96) | .02 |
| Connecticut | 0.97 (0.82-1.16) | .73 | 1.06 (0.88-1.27) | .51 |
| Detroit | 1.08 (0.92-1.27) | .34 | 1.27 (1.08-1.51) | .005 |
| Hawaii | 0.933 (0.64-1.35) | .71 | 0.93 (0.62-1.38) | .71 |
| Iowa | 0.60 (0.49-0.73) | < .0001 | 0.60 (0.49-0.74) | < .0001 |
| Kentucky | 0.77 (0.64-0.92) | .004 | 0.74 (0.61-0.89) | .001 |
| Louisiana | 0.87 (0.72-1.06) | .16 | 0.82 (0.67-1.002) | .052 |
| New Jersey | 0.81 (0.69-0.95) | .009 | 0.82 (0.70-0.97) | .02 |
| New Mexico | 0.92 (0.66-1.30) | .65 | 1.05 (0.74-1.48) | .80 |
| Seattle | 1.02 (0.82-1.27) | .85 | 1.02 (0.82-1.28) | .86 |
| Texas | 0.86 (0.76-0.98) | .02 | 1.02 (0.88-1.18) | .78 |
| Utah | 0.61 (0.38-1.0) | .05 | 0.70 (0.43-1.16) | .17 |
| Charlson comorbidity index vs 0 | ||||
| 1 | 1.10 (1.002-1.21) | .046 | 1.08 (0.98-1.19) | .11 |
| 2+ | 1.18 (1.05-1.31) | .004 | 1.15 (1.03-1.28) | .02 |
| T stage vs 1 | ||||
| 2 | 0.67 (0.60-0.74) | < .0001 | 0.62 (0.56-0.68) | < .0001 |
| 3 | 0.48 (0.40-0.57) | < .0001 | 0.42 (0.35-0.50) | < .0001 |
| Unknown | 0.48 (0.42-0.54) | < .0001 | 0.43 (0.37-0.50) | < .0001 |
| Small cell lung cancer vs NSCLC | 0.52 (0.45-0.60) | < .0001 | 0.53 (0.46-0.61) | < .0001 |
| Guideline consistent vs guideline inconsistent | 0.47 (41-0.53) | < .0001 | 0.42 (0.37-0.48) | < .0001 |
See Table 1 legend for expansion of abbreviation.